​

Arcutis Biotherapeutics (ARQT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ARQT Stock Forecast

Arcutis Biotherapeutics (ARQT) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $27.00, with a high of $51.00 and a low of $18.00. This represents a 37.47% increase from the last price of $19.64.

- $11 $22 $33 $44 $55 High: $51 Avg: $27 Low: $18 Last Closed Price: $19.64

ARQT Stock Rating

Arcutis Biotherapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (83.33%), 2 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 2 10 0 Strong Sell Sell Hold Buy Strong Buy

ARQT Price Target Upside V Benchmarks

TypeNameUpside
StockArcutis Biotherapeutics37.47%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$19.00
Last Closing Price$19.64$19.64$19.64
Upside/Downside---3.26%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25341--8
Sep, 25341--8
Aug, 25341--8
Jul, 2534---7
Jun, 2534---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 11, 2025Jefferies$19.00$15.4922.66%-3.26%
Dec 30, 2024Douglas TsaoH.C. Wainwright$19.00$14.2033.80%-3.26%
May 15, 2024Serge BelangerNeedham$18.00$8.13121.40%-8.35%
May 15, 2024Uy EarMizuho Securities$18.00$8.13121.40%-8.35%
Jan 02, 2024Mizuho Securities$8.00$3.43133.24%-59.27%
Dec 13, 2022Morgan Stanley$51.00$16.58207.60%159.67%
Apr 27, 2022Eric ChaGoldman Sachs$37.00$19.6288.58%88.39%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 07, 2025Cowen & Co.BuyBuyhold
Mar 11, 2025JefferiesBuyBuyhold
Dec 30, 2024H.C. WainwrightBuyinitialise
Aug 28, 2024NeedhamBuyBuyhold
Aug 28, 2024JefferiesBuyinitialise
Aug 15, 2024Cowen & Co.BuyBuyhold
Jul 10, 2024NeedhamBuyBuyhold
May 15, 2024NeedhamBuyBuyhold
Apr 12, 2024NeedhamBuyBuyhold
Dec 13, 2022Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$-7 $-5 $-3 $-1 $1 $3 $4 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.84$-3.78$-1.16----
Avg Forecast$-5.93$-3.92$-1.32$-0.83$0.05$1.51$2.44
High Forecast$-4.99$-3.81$-1.18$-0.56$0.20$3.23$2.82
Low Forecast$-6.73$-4.02$-1.38$-0.96$-0.11$0.14$2.15
Surprise %-1.52%-3.57%-12.12%----

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.69M$59.61M$196.54M----
Avg Forecast$2.97M$57.58M$185.46M$288.65M$423.15M$635.90M$788.81M
High Forecast$3.28M$64.49M$190.80M$311.07M$427.21M$712.20M$883.44M
Low Forecast$2.61M$52.28M$181.24M$267.54M$419.09M$577.34M$716.17M
Surprise %23.99%3.52%5.97%----

Net Income Forecast

$-500M $-350M $-200M $-50M $100M $250M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-321.29M$-262.14M$-140.04M----
Avg Forecast$-411.14M$-271.19M$-88.60M$-52.46M$3.08M$157.37M$168.97M
High Forecast$-345.49M$-263.71M$-81.47M$-38.68M$13.99M$223.66M$195.32M
Low Forecast$-466.18M$-278.68M$-95.73M$-66.23M$-7.84M$9.65M$148.74M
Surprise %-21.85%-3.34%58.05%----

ARQT Forecast FAQ

Is Arcutis Biotherapeutics stock a buy?

Arcutis Biotherapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcutis Biotherapeutics is a favorable investment for most analysts.

What is Arcutis Biotherapeutics's price target?

Arcutis Biotherapeutics's price target, set by 12 Wall Street analysts, averages $27 over the next 12 months. The price target range spans from $18 at the low end to $51 at the high end, suggesting a potential 37.47% change from the previous closing price of $19.64.

How does Arcutis Biotherapeutics stock forecast compare to its benchmarks?

Arcutis Biotherapeutics's stock forecast shows a 37.47% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Arcutis Biotherapeutics over the past three months?

  • October 2025: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Arcutis Biotherapeutics’s EPS forecast?

Arcutis Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.83, marking a -28.45% decrease from the reported $-1.16 in 2024. Estimates for the following years are $0.05 in 2026, $1.51 in 2027, and $2.44 in 2028.

What is Arcutis Biotherapeutics’s revenue forecast?

Arcutis Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $288.65M, reflecting a 46.86% increase from the reported $196.54M in 2024. The forecast for 2026 is $423.15M, followed by $635.9M for 2027, and $788.81M for 2028.

What is Arcutis Biotherapeutics’s net income forecast?

Arcutis Biotherapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-52.455M, representing a -62.54% decrease from the reported $-140M in 2024. Projections indicate $3.08M in 2026, $157.37M in 2027, and $168.97M in 2028.